This white paper explores the critical role of early autonomic neuropathy detection in improving patient outcomes, particularly for those with chronic metabolic conditions. It outlines clinical assessment strategies, integration of the VitalScan ANS+ System, and guidance on reimbursement models.
Autonomic neuropathy (AN) is a frequently underdiagnosed complication that significantly impacts morbidity and mortality across patient populations, particularly those with diabetes mellitus. Often overshadowed by peripheral neuropathy, AN affects the involuntary nervous system, leading to cardiovascular instability, gastrointestinal dysfunction, and urogenital issues. This document emphasizes the necessity of objective, non-invasive autonomic nervous system (ANS) testing for early detection. By leveraging technologies like the VitalScan ANS+ System, clinicians can identify subclinical deficits, implement early therapeutic interventions, and improve long-term outcomes while optimizing practice revenue through standardized CPT coding.
Autonomic neuropathy occurs when damage to the autonomic nerves disrupts the signals between the brain and internal organs. In diabetic patients, cardiac autonomic neuropathy (CAN) is associated with an increased risk of silent myocardial infarction and sudden cardiac death. Beyond diabetes, AN presents in Parkinson’s disease, POTS, and systemic autoimmune disorders. Early identification is vital, as the initial stages of nerve damage are often reversible or manageable through aggressive glycemic control and lifestyle modification.
Objective assessment of the ANS requires measuring the cardiovascular response to provocative maneuvers. The gold standard involves heart rate variability (HRV) analysis, deep breathing tests, and Valsalva maneuver monitoring. The VitalScan ANS+ System streamlines this process by integrating multi-parameter sensors that record ECG, blood pressure, and respiratory data in real-time. This allows for precise calculation of parasympathetic and sympathetic activity, providing a comprehensive report that exceeds subjective screening methods.
Integrating ANS testing into the clinical workflow requires minimal disruption to patient flow. 1. Pre-Screening: Identify high-risk patients during routine check-ups using validated questionnaires. 2. Testing: Perform a 15-20 minute session using the VitalScan ANS+ System, conducted by clinical staff under physician oversight. 3. Interpretation: The system generates an immediate report identifying autonomic balance. 4. Care Plan: The physician reviews the objective data to adjust medications, suggest physical therapy, or refer to specialists if deep-seated neuropathic damage is identified.
Autonomic testing is a reimbursable service under several CPT codes. CPT 95921 covers autonomic testing including tilt table and/or Valsalva, while CPT 95922 and 95924 provide additional coverage for sweat gland function and sympathetic skin response. Practices can also layer vascular assessments using CPT 93922-93971 where indicated. By offering these in-office services, practices capture high-value diagnostics that were previously outsourced, significantly improving practice margins and patient retention.
Early detection of autonomic neuropathy is the bridge between silent progression and managed health. By adopting the VitalScan ANS+ System, your practice gains the clinical precision needed to identify high-risk patients earlier than traditional methods allow. We invite you to contact US MedResources to request a personalized ROI analysis or a virtual demonstration of the VitalScan ANS+ system to see how it can transform your clinical practice.
Enter your email to download this clinical resource. We'll also send you a free ROI analysis for your practice.